VOR licensed telitacicept from RemeGen and appointed Jean-Paul Kress as CEO and Chairman of the company.
1 report, 0 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
VOR licensed telitacicept from RemeGen and appointed Jean-Paul Kress as CEO and Chairman of the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
VOR
company in the Czech Republic
Nothing else this week.
-
RemeGen Co., Ltd.
Nothing else this week.
-
Jean-Paul Kress
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet